Optimal Administration of Allopurinol in Dialysis Patients

• Status: Completed
• Trial end date: 2015-08-01
• Target enrollment: 0
• Participant gender: All

Summary

Gout has a strong association with the metabolic syndrome, and it is often seen in patients with renal insufficiency. Allopurinol is a medication intended to lower uric acid and therefore prevents gout attacks. Its metabolism is mainly renal, and some evidence shows that it is also dialyzable. The hypothesis is that allopurinol would be more efficacious to lower uric acid if it was given after dialysis only. The investigators will then switch administration of allopurinol to bedtime for dialysis patients currently taking that medication.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Maisonneuve-Rosemont Hospital
• Treatments: Allopurinol

Criteria

Inclusion Criteria:

• Subjects who receive chronic treatments of hemodialysis at Maisonneuve-Rosemont Hospital

• Subjects who take allopurinol for at least a month

Exclusion Criteria:

• Subjects who have had an acute gout attack in the past month

• Subjects with tumor lysis syndrome

• Sujects who have a history of hypersensitivity reaction to allopurinol

• Subjects with hepatic insufficiency

• Women who are pregnant or planning to become pregnant in the next three months